PomegraIDEXX Stock Jumps 20% After Q3 Earnings Beat
Why did IDEXX stock jump 20%?
IDEXX Laboratories (IDXX) stock jumped about 20% to above $660 on Monday after the pet diagnostics maker beat third-quarter earnings and sales estimates and raised its 2026 forecast.
Key numbers
| Q3 revenue | $1.214B+10% YoY |
|---|---|
| Comparable EPS | $3.96+22% YoY |
| CAG Diagnostics recurring revenue | +11%organic growth |
| 2026 EPS guidance | $14.96–$15.16from $14.69–$14.94 |
| Stock move Nov 2 | ~+20%+22% per Seeking Alpha |
| inVue Dx analyzers placed in Q3 | 1,900+~11,000 installed |
What happened
IDEXX Laboratories (IDXX) stock jumped about 20% to above $660 on Monday after the pet diagnostics maker beat third-quarter earnings and sales estimates and raised its 2026 forecast. Sales rose 10% from a year ago to $1.21 billion, and profit per share was $3.96 after adjusting for one-time items, above the roughly $3.72 analysts expected. Repeat lab and test revenue from pets (recurring revenue) grew 11%, and IDEXX lifted its full-year outlook (guidance). Some outlets put the day's gain nearer 22%, depending on the price used.
Why it matters
IDEXX makes the lab machines and tests that vets use to check pets' health, so its results show how much pet owners are still spending on care. The strong report suggests testing demand held up even though U.S. vet clinic visits fell an estimated 1.8%. IDEXX is part of the S&P 500, so a move this big also touches many index funds.
Who this affects
- MarketbullishMedium impact
- Good for IDEXX holders and S&P 500 index funds.
- CompanybullishHigh impact
- Good for shareholders: beat, raised outlook, shares up about 20%.
- CompetitorsbullishLow impact
- Zoetis shares rose 4.3% the same day, a mild lift.
- IndustrymixedMedium impact
- Pet testing demand holds up, but clinic visits are slipping.
IDEXX vs Zoetis, Elanco
How we got here
IDEXX reports Q1 2026 revenue of $1.141B, up 14% as reported.
IDEXX closes Friday trading at about 35 times forward earnings, below its five-year average of 45x.
IDEXX reports Q3 results and raises its 2026 revenue and profit outlook.
IDEXX shares jump about 20% in Monday trading.
What to watch
- Whether U.S. vet clinic visits, estimated down 1.8%, keep falling and weigh on test volumes.Q4 2026
- IDEXX's full-year operating margin, guided to 32.1%–32.3% after the CoVet acquisition.Q4 2026
- Pace of inVue Dx analyzer installs, now at roughly 11,000 units worldwide.Q4 2026
Educational content only. Not investment advice.
More briefsAll briefs →
Dow Rises 0.4% as Nasdaq Falls 1.1% in Tech Rotation
Sherwin-Williams (SHW) rose 5.9% and Home Depot (HD) 3.6% as investors moved money out of AI-heavy tech.
No new Xi visit to the White House this Thursday; the next Trump–Xi meeting is expected at APEC in Shenzhen
Xi's White House state visit was on 24 September. The trade truce now runs to 10 January 2027, and the leaders are expected to meet again on 18–19 November.
SpaceX Stock Rises 1.2% After Report of Boost Mobile Talks
SpaceX (SPCX) is reportedly in talks with EchoStar, up 1.3%, to speed up its Starlink Mobile push.